JP2016065086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016065086A5 JP2016065086A5 JP2015226794A JP2015226794A JP2016065086A5 JP 2016065086 A5 JP2016065086 A5 JP 2016065086A5 JP 2015226794 A JP2015226794 A JP 2015226794A JP 2015226794 A JP2015226794 A JP 2015226794A JP 2016065086 A5 JP2016065086 A5 JP 2016065086A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- apixaban
- composition according
- equal
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims 27
- 229960003886 apixaban Drugs 0.000 claims 27
- 239000012738 dissolution medium Substances 0.000 claims 11
- 239000002775 capsule Substances 0.000 claims 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 239000002994 raw material Substances 0.000 claims 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 4
- 239000001488 sodium phosphate Substances 0.000 claims 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 4
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30805610P | 2010-02-25 | 2010-02-25 | |
| US61/308,056 | 2010-02-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555127A Division JP5846647B2 (ja) | 2010-02-25 | 2011-02-24 | アピキサバン製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016209347A Division JP6192078B2 (ja) | 2010-02-25 | 2016-10-26 | アピキサバン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016065086A JP2016065086A (ja) | 2016-04-28 |
| JP2016065086A5 true JP2016065086A5 (enExample) | 2016-08-25 |
| JP6033945B2 JP6033945B2 (ja) | 2016-11-30 |
Family
ID=43901603
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555127A Active JP5846647B2 (ja) | 2010-02-25 | 2011-02-24 | アピキサバン製剤 |
| JP2015226794A Active JP6033945B2 (ja) | 2010-02-25 | 2015-11-19 | アピキサバン製剤 |
| JP2016209347A Active JP6192078B2 (ja) | 2010-02-25 | 2016-10-26 | アピキサバン製剤 |
| JP2017149644A Active JP6577980B2 (ja) | 2010-02-25 | 2017-08-02 | アピキサバン製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555127A Active JP5846647B2 (ja) | 2010-02-25 | 2011-02-24 | アピキサバン製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016209347A Active JP6192078B2 (ja) | 2010-02-25 | 2016-10-26 | アピキサバン製剤 |
| JP2017149644A Active JP6577980B2 (ja) | 2010-02-25 | 2017-08-02 | アピキサバン製剤 |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US9326945B2 (enExample) |
| EP (7) | EP3246021B1 (enExample) |
| JP (4) | JP5846647B2 (enExample) |
| KR (4) | KR20170126016A (enExample) |
| CN (3) | CN109602716A (enExample) |
| AU (1) | AU2011220775B2 (enExample) |
| BR (1) | BR112012021337A8 (enExample) |
| CA (1) | CA2791171C (enExample) |
| CO (1) | CO6640207A2 (enExample) |
| CY (5) | CY1117434T1 (enExample) |
| DK (5) | DK3257500T3 (enExample) |
| ES (5) | ES2757603T3 (enExample) |
| HK (2) | HK1243947B (enExample) |
| HR (5) | HRP20160179T1 (enExample) |
| HU (4) | HUE047140T2 (enExample) |
| IL (3) | IL309564A (enExample) |
| IN (1) | IN2012DN06587A (enExample) |
| LT (4) | LT3257500T (enExample) |
| MX (3) | MX2012009244A (enExample) |
| NZ (1) | NZ601738A (enExample) |
| PE (3) | PE20130378A1 (enExample) |
| PL (5) | PL3246021T3 (enExample) |
| PT (5) | PT3246021T (enExample) |
| RS (5) | RS59810B1 (enExample) |
| RU (1) | RU2685724C2 (enExample) |
| SG (2) | SG182750A1 (enExample) |
| SI (5) | SI3257500T1 (enExample) |
| SM (5) | SMT201900212T1 (enExample) |
| TR (1) | TR201903195T4 (enExample) |
| WO (1) | WO2011106478A2 (enExample) |
| ZA (1) | ZA201205807B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109602716A (zh) | 2010-02-25 | 2019-04-12 | 百时美-施贵宝爱尔兰控股无限责任公司 | 包含药物组合物的片剂或胶囊剂 |
| WO2013164839A2 (en) * | 2012-03-06 | 2013-11-07 | Cadila Healthcare Limited | Amorphous form of apixaban, process of preparation and compositions thereof |
| WO2013174498A1 (en) * | 2012-05-24 | 2013-11-28 | Ratiopharm Gmbh | Dosage forms comprising apixaban and matrix former |
| WO2014052678A1 (en) * | 2012-09-26 | 2014-04-03 | Bristol-Myers Squibb Company | Apixaban liquid formulations |
| CN102908324A (zh) * | 2012-10-31 | 2013-02-06 | 南京正科制药有限公司 | 一种阿哌沙班片 |
| EP2752414A1 (en) | 2013-01-04 | 2014-07-09 | Sandoz AG | Crystalline form of apixaban |
| CZ2013305A3 (cs) | 2013-04-23 | 2014-11-05 | Zentiva, K.S. | Nové krystalické formy APIXABANU a způsob jejich přípravy |
| WO2014203275A2 (en) * | 2013-06-18 | 2014-12-24 | Cadila Healthcare Limited | An improved process for the preparation of apixaban and intermediates thereof |
| EP2907507A1 (en) * | 2014-02-17 | 2015-08-19 | Sandoz Ag | Pharmaceutical composition comprising apixaban |
| CN103830199A (zh) * | 2014-03-24 | 2014-06-04 | 重庆东得医药科技有限公司 | 含阿哌沙班的药用制剂及其制备方法 |
| CA2954840A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide |
| CN104316637B (zh) * | 2014-10-30 | 2016-08-17 | 江苏宝众宝达药业有限公司 | 高效液相色谱法测定阿哌沙班清洗残留量 |
| US9603846B2 (en) | 2014-11-25 | 2017-03-28 | Cadila Healthcare Limited | Process for the preparation of apixaban |
| WO2016181276A1 (en) * | 2015-05-08 | 2016-11-17 | Wockhardt Limited | Stable pharmaceutical compositions comprising antibacterial agent |
| EP3380083A1 (en) | 2015-11-26 | 2018-10-03 | Zentiva, K.S. | Preparation of a drug form containing amorphous apixaban |
| CN106913528A (zh) * | 2015-12-25 | 2017-07-04 | 中美华世通生物医药科技（武汉）有限公司 | 阿哌沙班微丸及其制备方法 |
| WO2017121340A1 (zh) * | 2016-01-12 | 2017-07-20 | 广东东阳光药业有限公司 | 阿哌沙班固体组合物及其制备方法 |
| EP3195860A1 (de) * | 2016-01-22 | 2017-07-26 | STADA Arzneimittel AG | Verfahren zur herstellung eines apixaban-granulates |
| WO2017163170A1 (en) * | 2016-03-21 | 2017-09-28 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition comprising apixaban |
| WO2017182908A1 (en) * | 2016-04-18 | 2017-10-26 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of apixaban |
| EP3243505A1 (en) | 2016-05-13 | 2017-11-15 | Zaklady Farmaceutyczne Polpharma SA | A pharmaceutical composition comprising amorphous apixaban |
| CN106822006B (zh) * | 2016-06-08 | 2020-08-28 | 北京普德康利医药科技发展有限公司 | 一种阿哌沙班片及其制备方法 |
| WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
| TN2019000063A1 (en) * | 2016-09-24 | 2020-07-15 | Kbp Biosciences Co Ltd | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof |
| CN106420651B (zh) * | 2016-09-28 | 2019-03-08 | 乐普药业股份有限公司 | 一种阿哌沙班片的制备方法 |
| EP3582777A4 (en) | 2017-02-17 | 2020-12-23 | Unichem Laboratories Ltd | PHARMACEUTICAL COMPOSITION OF APIXABAN |
| JP7044115B2 (ja) | 2017-11-27 | 2022-03-30 | 三菱ケミカル株式会社 | ゴム含有グラフト重合体組成物を含む熱可塑性樹脂の樹脂改質用組成物、ゴム含有グラフト重合体含有樹脂組成物およびその成形体 |
| KR20190075566A (ko) | 2017-12-21 | 2019-07-01 | 전자부품연구원 | 다중 센서를 활용한 용변 습관 모니터링 시스템 및 방법 |
| TR201722523A2 (tr) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Api̇ksaban i̇çeren kati oral farmasöti̇k kompozi̇syonlar |
| CN108236604A (zh) * | 2018-02-07 | 2018-07-03 | 中国药科大学 | 阿哌沙班柔性脂质体 |
| ES2988919T3 (es) | 2018-04-16 | 2024-11-22 | Bristol Myers Squibb Co | Formulaciones de apixaban |
| KR20190130411A (ko) * | 2018-05-14 | 2019-11-22 | 신일제약주식회사 | 아픽사반 약제학적 제제 및 그의 제조방법 |
| JP2021535094A (ja) | 2018-08-14 | 2021-12-16 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. | 注射可能な医薬組成物およびその調製方法 |
| EP3666773A1 (en) | 2018-12-11 | 2020-06-17 | KRKA, D.D., Novo Mesto | Process for preparing apixaban |
| EP3669866A1 (en) | 2018-12-19 | 2020-06-24 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising apixaban |
| CN111377915B (zh) * | 2018-12-30 | 2023-10-24 | 鲁南制药集团股份有限公司 | 一种吡唑并-吡啶酮化合物晶型d |
| CN109464415B (zh) * | 2019-01-09 | 2021-08-17 | 常州恒邦药业有限公司 | 阿哌沙班药物组合物及其制备方法 |
| MA55568A (fr) | 2019-11-13 | 2022-02-09 | Unison Pharmaceuticals Pvt Ltd | Compositions pharmaceutiques orodispersibles d'apixaban |
| CN111214442B (zh) * | 2020-02-13 | 2021-12-10 | 山东百诺医药股份有限公司 | 一种阿哌沙班共微粉化物 |
| CN111494326A (zh) * | 2020-04-11 | 2020-08-07 | 南京正大天晴制药有限公司 | 一种阿哌沙班片及其制备方法 |
| WO2022115051A1 (en) | 2020-11-27 | 2022-06-02 | Santa Farma Ilac Sanayii A.S. | Direct compression method for non-micronised apixaban formulations |
| WO2022115052A1 (en) | 2020-11-27 | 2022-06-02 | Santa Farma Ilac Sanayii A.S. | Improved wet granulation processes for apixaban comprising formulations |
| WO2022150030A2 (en) | 2021-01-08 | 2022-07-14 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A film coated tablet of apixaban |
| TR202100250A2 (tr) | 2021-01-08 | 2022-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Api̇ksaban i̇çeren fi̇lm kapli tablet |
| JP2022112698A (ja) * | 2021-01-22 | 2022-08-03 | 東和薬品株式会社 | アピキサバン含有医薬組成物 |
| GB202102575D0 (en) | 2021-02-23 | 2021-04-07 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
| IL309098A (en) * | 2021-06-08 | 2024-02-01 | Taho Pharmaceuticals Ltd | Apixaban layer product and its uses |
| EP4412586A1 (en) | 2021-10-27 | 2024-08-14 | Pharma-Data S.A. | Apixaban suspension and preparation method |
| JP2024057549A (ja) * | 2022-10-12 | 2024-04-24 | 日本ジェネリック株式会社 | アピキサバンを含有する錠剤 |
| KR102760108B1 (ko) | 2024-04-09 | 2025-01-24 | 에바바이오 주식회사 | 수용해도와 투과도를 향상시켜 생체이용률이 개선된 무정형 아픽사반 고체분산체 제제 및 그의 서방성 정제 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150366A (en) | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
| ES2232202T3 (es) | 1998-12-23 | 2005-05-16 | Bristol-Myers Squibb Pharma Company | Heterobiciclos que contienen nitrogeno como inhibidores del factor xa. |
| TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| HRP20080382A2 (en) | 2001-09-21 | 2008-12-31 | Bristol-Myers Squibb Company A Delaware (Usa) Corporation | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS |
| WO2004084943A1 (en) * | 2003-03-19 | 2004-10-07 | Beth Israel Deaconess Medical Center, Inc | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation |
| US20050059719A1 (en) * | 2003-09-16 | 2005-03-17 | Badawy Sherif Ibrahim Farag | Solid dosage formulation containing a Factor Xa inhibitor and method |
| DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| US7434502B2 (en) | 2004-07-21 | 2008-10-14 | Husqvarna Outdoor Products Inc. | Bar knob with cam-operated locking mechanism |
| US20060016084A1 (en) * | 2004-07-24 | 2006-01-26 | Ching-Lin Liao | Laser-Based datum instrument |
| US7396932B2 (en) | 2004-09-28 | 2008-07-08 | Bristol-Myers Squibb Company | Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US20060160841A1 (en) * | 2005-01-19 | 2006-07-20 | Chenkou Wei | Crystallization via high-shear transformation |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| EP1951197A4 (en) | 2005-11-10 | 2011-12-21 | Alphapharm Pty Ltd | METHOD OF CHECKING THE PARTICLE SIZE |
| US20070259913A1 (en) | 2006-05-04 | 2007-11-08 | David Deitchman | Prophylaxis of thromboembolic events in cancer patients |
| EP2061439A1 (en) * | 2006-09-12 | 2009-05-27 | Glaxo Group Limited | Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor |
| FI20080351A0 (fi) * | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi |
| EP2586439A1 (en) * | 2007-05-02 | 2013-05-01 | Portola Pharmaceuticals, Inc. | Combination therapy with a compound acting as a platelet ADP receptor inhibitor |
| US20090143343A1 (en) * | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| WO2009135946A1 (en) * | 2008-05-09 | 2009-11-12 | Atacama Labs Oy | Method and apparatus for dry granulation |
| KR20110043655A (ko) | 2008-07-11 | 2011-04-27 | 바스프 에스이 | 모폴로지 변경제로서의 양친매성 단백질 |
| US20100018486A1 (en) * | 2008-07-22 | 2010-01-28 | Hung-Tao Liu | Cathode energy fuel-saving device |
| EP4008327A1 (en) * | 2009-04-29 | 2022-06-08 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| SMT202000093T1 (it) | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
| CN109602716A (zh) * | 2010-02-25 | 2019-04-12 | 百时美-施贵宝爱尔兰控股无限责任公司 | 包含药物组合物的片剂或胶囊剂 |
| WO2011110930A2 (en) * | 2010-03-10 | 2011-09-15 | Lupin Limited | Rifaximin ready-to-use suspension |
-
2011
- 2011-02-24 CN CN201810769647.9A patent/CN109602716A/zh active Pending
- 2011-02-24 SG SG2012055547A patent/SG182750A1/en unknown
- 2011-02-24 EP EP17175864.2A patent/EP3246021B1/en not_active Revoked
- 2011-02-24 DK DK17178613T patent/DK3257500T3/da active
- 2011-02-24 JP JP2012555127A patent/JP5846647B2/ja active Active
- 2011-02-24 WO PCT/US2011/025994 patent/WO2011106478A2/en not_active Ceased
- 2011-02-24 SM SM20190212T patent/SMT201900212T1/it unknown
- 2011-02-24 SI SI201131813T patent/SI3257500T1/sl unknown
- 2011-02-24 PL PL17175864T patent/PL3246021T3/pl unknown
- 2011-02-24 PL PL17178613T patent/PL3257500T3/pl unknown
- 2011-02-24 HU HUE17178613A patent/HUE047140T2/hu unknown
- 2011-02-24 HR HRP20160179TT patent/HRP20160179T1/hr unknown
- 2011-02-24 SG SG10201501349VA patent/SG10201501349VA/en unknown
- 2011-02-24 SM SM20190649T patent/SMT201900649T1/it unknown
- 2011-02-24 PT PT171758642T patent/PT3246021T/pt unknown
- 2011-02-24 NZ NZ601738A patent/NZ601738A/en unknown
- 2011-02-24 PT PT171786130T patent/PT3257500T/pt unknown
- 2011-02-24 RS RS20200017A patent/RS59810B1/sr unknown
- 2011-02-24 EP EP20151141.7A patent/EP3662899A1/en not_active Withdrawn
- 2011-02-24 MX MX2012009244A patent/MX2012009244A/es active IP Right Grant
- 2011-02-24 SI SI201131811T patent/SI3251660T1/sl unknown
- 2011-02-24 RU RU2012140690A patent/RU2685724C2/ru active
- 2011-02-24 LT LT17178613T patent/LT3257500T/lt unknown
- 2011-02-24 PT PT15190823T patent/PT3017811T/pt unknown
- 2011-02-24 HU HUE15190823A patent/HUE043932T2/hu unknown
- 2011-02-24 LT LTEP17175864.2T patent/LT3246021T/lt unknown
- 2011-02-24 LT LT17175788T patent/LT3251660T/lt unknown
- 2011-02-24 EP EP17175788.3A patent/EP3251660B1/en not_active Revoked
- 2011-02-24 KR KR1020177031997A patent/KR20170126016A/ko not_active Ceased
- 2011-02-24 DK DK15190823.3T patent/DK3017811T3/en active
- 2011-02-24 PT PT117072843T patent/PT2538925E/pt unknown
- 2011-02-24 PL PL17175788T patent/PL3251660T3/pl unknown
- 2011-02-24 MX MX2017016605A patent/MX364938B/es unknown
- 2011-02-24 SI SI201131665T patent/SI3017811T1/sl unknown
- 2011-02-24 RS RS20190290A patent/RS58699B1/sr unknown
- 2011-02-24 PL PL15190823T patent/PL3017811T3/pl unknown
- 2011-02-24 HU HUE11707284A patent/HUE027168T2/en unknown
- 2011-02-24 CN CN201811354155.XA patent/CN109602713A/zh active Pending
- 2011-02-24 PL PL11707284T patent/PL2538925T3/pl unknown
- 2011-02-24 LT LTEP15190823.3T patent/LT3017811T/lt unknown
- 2011-02-24 IN IN6587DEN2012 patent/IN2012DN06587A/en unknown
- 2011-02-24 PE PE2012001362A patent/PE20130378A1/es not_active Application Discontinuation
- 2011-02-24 IL IL309564A patent/IL309564A/en unknown
- 2011-02-24 EP EP11707284.3A patent/EP2538925B1/en not_active Revoked
- 2011-02-24 MX MX2015007763A patent/MX353145B/es unknown
- 2011-02-24 DK DK17175788T patent/DK3251660T3/da active
- 2011-02-24 CA CA2791171A patent/CA2791171C/en active Active
- 2011-02-24 DK DK17175864.2T patent/DK3246021T3/da active
- 2011-02-24 TR TR2019/03195T patent/TR201903195T4/tr unknown
- 2011-02-24 ES ES17178613T patent/ES2757603T3/es active Active
- 2011-02-24 EP EP17178613.0A patent/EP3257500B1/en not_active Revoked
- 2011-02-24 US US13/579,796 patent/US9326945B2/en active Active
- 2011-02-24 PE PE2020000316A patent/PE20210468A1/es unknown
- 2011-02-24 RS RS20160088A patent/RS54559B1/sr unknown
- 2011-02-24 PT PT171757883T patent/PT3251660T/pt unknown
- 2011-02-24 SM SM20190650T patent/SMT201900650T1/it unknown
- 2011-02-24 ES ES11707284.3T patent/ES2562279T3/es active Active
- 2011-02-24 KR KR1020217031947A patent/KR20210124532A/ko not_active Ceased
- 2011-02-24 KR KR1020237035193A patent/KR20230149861A/ko not_active Ceased
- 2011-02-24 ES ES17175788T patent/ES2758031T3/es active Active
- 2011-02-24 HU HUE17175788A patent/HUE047139T2/hu unknown
- 2011-02-24 ES ES15190823T patent/ES2714363T3/es active Active
- 2011-02-24 EP EP15190823.3A patent/EP3017811B1/en not_active Revoked
- 2011-02-24 SM SM20200034T patent/SMT202000034T1/it unknown
- 2011-02-24 BR BR112012021337A patent/BR112012021337A8/pt not_active Application Discontinuation
- 2011-02-24 KR KR1020127022152A patent/KR101796300B1/ko not_active Ceased
- 2011-02-24 PE PE2015002402A patent/PE20160042A1/es unknown
- 2011-02-24 SI SI201131827T patent/SI3246021T1/sl unknown
- 2011-02-24 DK DK11707284.3T patent/DK2538925T3/en active
- 2011-02-24 AU AU2011220775A patent/AU2011220775B2/en active Active
- 2011-02-24 RS RS20191493A patent/RS59593B1/sr unknown
- 2011-02-24 ES ES17175864T patent/ES2767848T3/es active Active
- 2011-02-24 SI SI201130742T patent/SI2538925T1/sl unknown
- 2011-02-24 CN CN201180011229XA patent/CN102770126A/zh active Pending
- 2011-02-24 RS RS20191468A patent/RS59576B1/sr unknown
- 2011-02-24 EP EP19199147.0A patent/EP3643301A1/en not_active Withdrawn
-
2012
- 2012-07-22 IL IL221064A patent/IL221064A0/en unknown
- 2012-08-01 ZA ZA2012/05807A patent/ZA201205807B/en unknown
- 2012-09-05 CO CO12152138A patent/CO6640207A2/es not_active Application Discontinuation
-
2015
- 2015-11-19 JP JP2015226794A patent/JP6033945B2/ja active Active
-
2016
- 2016-02-17 SM SM201600049T patent/SMT201600049B/xx unknown
- 2016-03-07 CY CY20161100194T patent/CY1117434T1/el unknown
- 2016-03-31 US US15/086,447 patent/US20160243101A1/en not_active Abandoned
- 2016-10-26 JP JP2016209347A patent/JP6192078B2/ja active Active
-
2017
- 2017-03-30 US US15/474,236 patent/US20170202824A1/en not_active Abandoned
- 2017-03-30 US US15/474,264 patent/US20170202825A1/en not_active Abandoned
- 2017-04-27 IL IL251991A patent/IL251991A0/en unknown
- 2017-08-02 JP JP2017149644A patent/JP6577980B2/ja active Active
-
2018
- 2018-03-14 HK HK18103544.5A patent/HK1243947B/en not_active IP Right Cessation
- 2018-03-14 HK HK18103542.7A patent/HK1243945B/en not_active IP Right Cessation
-
2019
- 2019-02-28 CY CY20191100249T patent/CY1121597T1/el unknown
- 2019-03-05 HR HRP20190430TT patent/HRP20190430T8/hr unknown
- 2019-11-15 HR HRP20192064TT patent/HRP20192064T1/hr unknown
- 2019-11-18 HR HRP20192069TT patent/HRP20192069T1/hr unknown
- 2019-11-21 CY CY20191101226T patent/CY1122382T1/el unknown
- 2019-11-22 CY CY20191101231T patent/CY1122384T1/el unknown
-
2020
- 2020-01-13 HR HRP20200046TT patent/HRP20200046T1/hr unknown
- 2020-01-28 CY CY20201100074T patent/CY1122529T1/el unknown
- 2020-05-14 US US15/931,910 patent/US20200375968A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016065086A5 (enExample) | ||
| JP6875407B2 (ja) | Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
| IL283152B1 (en) | Preparations containing a high dose of a tetracyclic compound, methods for their preparation and their uses | |
| JP2012031131A5 (enExample) | ||
| JP2015535289A5 (enExample) | ||
| UA110853C2 (uk) | Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування | |
| JP2009235073A5 (enExample) | ||
| JPS59222475A (ja) | 二相薬剤組成物 | |
| KR102759845B1 (ko) | 2-｛4-[n-(5,6-디페닐피라진-2-일)-n-이소프로필아미노]부틸옥시｝-n-(메틸술포닐)아세트아미드를 함유하는 의약 조성물 | |
| CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| HRP20220332T1 (hr) | Farmaceutski pripravak koji sadrži drospirenon za uporabu kao kontraceptiv | |
| ES2606307T3 (es) | Producto de co-micronización que comprende acetato de ulipristal | |
| CA2687741A1 (en) | Stabilized amorphous forms of imatinib mesylate | |
| EP2432459A2 (en) | Oral compositions of celecoxib | |
| JP2015510916A5 (enExample) | ||
| WO2011160541A1 (zh) | 托伐普坦固体分散体及其制备方法 | |
| CN106176640B (zh) | 一种含枸橼酸托法替布的药物组合物及其制备方法 | |
| CN104721156B (zh) | 一种含利伐沙班的片剂 | |
| JPWO2013100112A1 (ja) | アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物 | |
| CN103860511B (zh) | 一种含有厄贝沙坦和苯磺酸氨氯地平的药用组合物及其制备方法 | |
| JP6485120B2 (ja) | 固形製剤 | |
| CN104173303B (zh) | 一种含有利奈唑胺的组合物及其制备方法 | |
| JP2013043834A (ja) | 溶出改善固形製剤 | |
| CN102872019A (zh) | 一种采用微粉化技术的依非韦伦制剂 | |
| CN101862335B (zh) | 一种含吗替麦考酚酯的药物组合物 |